SCHEMBL4039719

SCHEMBL4039719

COC(=O)c1ccc(N(C)C(=O)OC(C)(C)C)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NOTUM Q6P988 1/20 0.43
TTK P33981 1/20 0.39
ALDH1A1 P00352 1/20 0.39
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.37
HCAR3 P49019 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
CA12 O43570 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29996325 1.00 MAPK1 (0.49) MAPK1KDM4EL3MBTL1NOTUMTTK
SCHEMBL6882614 0.89 MAPK1 (0.51) MAPK1KDM4EL3MBTL1NOTUMALDH1A1
SCHEMBL691501 0.86 HCAR3 (0.51) KDM4EL3MBTL1ALDH1A1MAPTHCAR3
SCHEMBL692389 0.84 HCAR3 (0.38) TTKALDH1A1HCAR3CA1CA2
SCHEMBL693629 0.83 MAPK1 (0.46) MAPK1KDM4EL3MBTL1NOTUMALDH1A1
SCHEMBL24774145 0.80 MAPK1 (0.43) MAPK1KDM4EL3MBTL1NOTUMALDH1A1
SCHEMBL20037705 0.80 TTK (0.39) KDM4ETTKALDH1A1RAB9ANPC1
SCHEMBL16989275 0.80 KDM4E (0.47) MAPK1KDM4EL3MBTL1NOTUMALDH1A1
SCHEMBL3296861 0.79 ALDH1A1 (0.53) KDM4ETTKALDH1A1RAB9ANPC1
SCHEMBL1872796 0.79 MAPK1 (0.61) MAPK1KDM4EL3MBTL1ALDH1A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158385-A1 NOVEL COMPOUNDS Cerevance, Inc. 2024-05-16 US disclosed
EP-4288433-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2023-12-13 EP disclosed
WO-2022167819-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2022-08-11 WO disclosed
EP-1268443-B1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2009-07-29 EP disclosed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 EP disclosed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158385-A1 NOVEL COMPOUNDS KCNK3, KCNA4, KCNK13 MAPK1 1560/4885KDM4E 851/4885L3MBTL1 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.